The associations between HNSCC patient's outcome following cetuximab treatment and lncRNA-containing fusions or the CD274-PDCD1LG2 fusion deserve validation in prospective clinical trials. The gene discussed is PDCD1LG2; the disease is head and neck squamous cell carcinoma.